Page 148 - 2019年11月第30卷第21期

tivity and metabolism of 20-hydroxyeicosatetraenoic acid [30] PERL L，LERMAN-SHIVEK H，RECHAVIA E，et al. Re-
in the human platelet[J]. Br J Pharmacol，1992，106（2）： sponse to prasugrel and levels of circulating reticulated
267-274. platelets in patients with ST-segment elevation myocardial
[18] STEC DE，ROMAN RJ，AVERIA F，et al. Functional poly- infarction[J]. J Am Coll Cardiol，2014，63（6）：513-517.
morphism in human CYP4F2 decreases 20-HETE produc- [31] STRATZ C，NUHRENBERG T，AMANN M，et al. Im-
tion[J]. Physiol Genomics，2007，30（1）：74-81. pact of reticulated platelets on antiplatelet response to thi-
[19] TATARUNAS V，KUPSTYTE N，GIEDRAITIENE A， enopyridines is independent of platelet turnover[J]. Thromb
et al. The impact of CYP2C19*2，CYP4F2*3，and clinical Haemost，2016，116（5）：941-948.
factors on platelet aggregation，CYP4F2 enzyme activity， [32] VERDOIA M，PERGOLINI P，ROLLA R，et al. Impact of
and 20-hydroxyeicosatetraenoic acid concentration in pa- immature platelet fraction on platelet reactivity during pra-
tients treated with dual antiplatelet therapy[J]. Blood Co- sugrel maintenance treatment[J]. Platelets，2018.DOI：
agul Fibrinolysis，2017，28（8）：658-664. 10.1080/09537104.2018.1535707.
[20] NYLANDER S，FEMIA EA，SCAVONE M，et al. Ticagre- [33] VADUGANATHAN M，ZEMER-WASSERCUG N，RE-
lor inhibits human platelet aggregation via adenosine in CHAVIA E，et al. Relation between ticagrelor response
addition to P2Y12 antagonism[J]. J Thromb Haemost， and levels of circulating reticulated platelets in patients
2013，11（10）：1867-1876. with non-ST elevation acute coronary syndromes[J]. J
[21] DAVI G，PATRONO C. Platelet activation and athero- Thromb Thrombolysis，2015，40（2）：211-217.
thrombosis[J]. N Engl J Med，2007，357（24）：2482-2494. [34] STRATZ C，NUHRENBERG T，VALINA CM，et al. Im-
[22] WARD JL，SHERALI A，MO ZP，et al. Kinetic and phar- pact of reticulated platelets on the antiplatelet effect of the
macological properties of cloned human equilibrative nu- intravenous P2Y12-receptor inhibitor cangrelor[J]. Thromb
cleoside transporters，ENT1 and ENT2，stably expressed Haemost，2018，118（2）：362-368.
in nucleoside transporter-deficient PK15 cells. Ent2 exhib- [35] ROLLINI F，FRANCHI F，ANGIOLILLO DJ. Drug-drug
its a low affinity for guanosine and cytidine but a high af- interactions when switching between intravenous and oral
finity for inosine[J]. J Biol Chem，2000，275（12）：8375- P2Y12 receptor inhibitors：how real is it?[J]. JACC Car-
8381. diovasc Interv，2017，10（2）：130-132.
[23] VAN GIEZEN JJ，SIDAWAY J，GLAVES P，et al. Ticagre- [36] ANGIOLILLO DJ，ROLLINI F，STOREY RF，et al. Inter-
lor inhibits adenosine uptake in vitro and enhances adenos- national expert consensus on switching platelet P2Y12 re-
ine-mediated hyperemia responses in a canine model[J]. J ceptor-inhibiting therapies[J]. Circulation，2017，136（20）：
Cardiovasc Pharmacol Ther，2012，17（2）：164-172. 1955-1975.
[24] NARDIN M，VERDOIA M，PERGOLINI P，et al. Impact [37] ANGIOLILLO DJ，CURZEN N，GURBEL P，et al. Phar-
of adenosine A2a receptor polymorphism rs5751876 on macodynamic evaluation of switching from ticagrelor to
platelet reactivity in ticagrelor treated patients[J]. Pharma- prasugrel in patients with stable coronary artery disease：
col Res，2018.DOI：10.1016/j.phrs.2017.12.035. results of the SWAP-2 study（switching antiplatelet-2）[J].
[25] 张延京，王刚.血小板相关参数在血小板减少性疾病诊断 J Am Coll Cardiol，2014，63（15）：1500-1509.
中的临床意义[J].临床和实验医学杂志，2013，12（19）： [38] ALEXOPOULOS D，GALATI A，XANTHOPOULOU I，
1533-1535. et al. Ticagrelor versus prasugrel in acute coronary syn-
[26] 侍冬成，封启明，杨柳.网织血小板百分比增加与阿司匹 drome patients with high on-clopidogrel platelet reactivity
林抵抗的关系[J].中国药房，2008，19（29）：2280-2282. following percutaneous coronary intervention：a pharma-
[27] CESARI F，MARCUCCI R，GORI AM，et al. Reticulated codynamic study[J]. J Am Coll Cardiol，2012，60（3）：
platelets predict cardiovascular death in acute coronary 193-199.
syndrome patients. Insights from the AMI-Florence 2 [39] FRANCHI F，FAZ GT，ROLLINI F，et al. Pharmacody-
study[J]. Thromb Haemost，2013，109（5）：846-853. namic effects of switching from prasugrel to ticagrelor：re-
[28] PONS I，MONTEAGUDO M，LUCCHETTI G，et al. Cor- sults of the prospective，randomized SWAP-3 study[J].
relation between immature platelet fraction and reticulated JACC Cardiovasc Interv，2016，9（11）：1089-1098.
platelets. Usefulness in the etiology diagnosis of thrombo- [40] BASSEZ C，DEHARO P，PANKERT M，et al. Effective-
cytopenia[J]. Eur J Haematol，2010，85（2）：158-163. ness of switching low responders’to prasugrel to ticagre-
[29] BERNLOCHNER I，GOEDEL A，PLISCHKE C，et al. Im- lor after acute coronary syndrome[J]. Int J Cardiol，2014，
pact of immature platelets on platelet response to ticagre- 176（3）：1184-1185.
lor and prasugrel in patients with acute coronary syndrome [41] STEINHUBL SR，OH JJ，OESTREICH JH，et al. Transi-
[J]. Eur Heart J，2015，36（45）：3202-3210. tioning patients from cangrelor to clopidogrel：pharmaco-

中国药房 2019年第30卷第21期 China Pharmacy 2019 Vol. 30 No. 21 ·3023 ·